In partnership with Guideline Central, Endocrine Society has developed an educational package to improve knowledge and competencies for assessment, management, and treatment, especially with new therapies, for postmenopausal osteoporosis, and how to optimally use these guidelines in clinical practice.

This guideline toolkit aims to provide: 

• Increased knowledge to endocrinologists and allied providers managing patients with postmenopausal osteoporosis, in an engaging manner.
• Knowledge to clinicians who do not treat high-risk patients on a regular basis but will nonetheless benefit from insights gained because of this digital toolkit on emerging therapies.

Additionally, these guidelines take steps towards improving outcomes for patients who suffer from postmenopausal osteoporosis. 

Current Management and Future Direction of Basal Insulin

Looking for clarity on where basal insulin fits into today’s diabetes treatment paradigm? Curious about the latest evidence and utility of once-weekly formulations in development? Leading experts address real-world challenges, individualized treatment, and the case for basal insulin in current and future diabetes management a series of Medical Minutes and Clinical Thought activities.

Connecting the Mechanisms of Action to Patient Outcomes: Integrating the Latest Treatments for T2D Into Patient Care

Expert faculty review the mechanism of action of SGLT2 inhibitors, GLP-1 receptor agonists, and GIP/GLP-1 coagonists, and describe how knowledge of these actions can be used to guide treatment for patients with T2D and overweight or obesity.

Faculty: Vivian A. Fonseca, MD, FRCP, Jennifer B. Green, MD, Carol Hatch Wysham, MD

Statements: Provided by Clinical Care Options, LLC in partnership with the Endocrine Society.
Supported by an educational grant from Lilly.